Evio Venture Capital

# Evio Venture Capital: Correcting the Record

I need to address a significant inaccuracy in your query premise. Evio Venture Capital is not Singapore-based, nor does it have 2 unicorns in its portfolio. The firm is headquartered in Delaware, United States and operates with a focus on the US and UK markets.[4] Let me provide you with the accurate picture of this investment firm.

High-Level Overview

Evio Venture Capital is a mission-driven early-stage venture capital firm that has fundamentally reimagined how venture capital operates by placing founder wellbeing and peak performance at the center of its investment thesis.[1] Rather than treating venture capital as purely a financial transaction, Evio combines capital deployment with structured support for founder mental health, recognizing that sustainable company building requires sustainable founders.

The firm invests across the mental health and wellness ecosystem, backing care providers (particularly for serious mental illness), provider tools in SaaS form, digital therapeutics, neurotech, and wellness platforms.[3] Evio's investment stages span from idea and patent stage through early revenue, with typical check sizes ranging from $200,000 to $1 million.[3] The firm's impact extends beyond portfolio returns—it actively shapes the mental health innovation ecosystem through thought leadership and founder advocacy.

Origin Story

Evio was founded by Saki Georgiadis, a General Partner with deep roots in both private equity and mental health investing.[2] Georgiadis began investing in mental health and wellness in 2012, positioning himself as an early-stage believer in what would become iconic companies in the space. His early investor portfolio includes Calm, BetterUp, Foresight Mental Health, and Grow Therapy—demonstrating prescient conviction in the mental health technology wave before it became mainstream.[2]

Prior to founding Evio, Georgiadis spent his early career in private equity, working across New York, London, and Singapore, where he set up offices and built high-performance investment teams. He executed numerous healthcare deals that delivered 2.5x returns, establishing credibility in the sector.[2] Critically, Georgiadis also developed expertise as a talent management consultant for PE funds, designing CEO assessment processes—a capability that directly informed Evio's proprietary founder assessment methodology.

The founding team expanded to include Christy Maselli (Operating Partner), who transitioned from neuropsychology research into business operations and served as Chief of Staff to the COO of Technology at Bridgewater Associates, the world's largest hedge fund by assets under management. Maselli's operational pedigree was further refined at Grow Therapy, where she joined as the first non-founder employee post-Pre-Seed and helped scale the company to over $800 million in revenue and 400+ employees.[2] Matt Milford (Operating Partner) brings extensive mental health ecosystem knowledge, having founded the Global Institute of Mental & Brain Health Investment (GIMBHI) in 2019, whose research has been featured by McKinsey, Bessemer Venture Partners, Axios, Business Insider, Nature, and JPMorgan.[2]

Core Differentiators

Founder-Centric Investment Model

Evio's most distinctive feature is its inversion of traditional venture capital priorities. Rather than optimizing purely for financial returns, the firm explicitly structures its value proposition around founder wellbeing. This includes mental health support, coaching and mentoring from successful founders, and access to an advisory network.[3] Portfolio founders consistently highlight this differentiation—one founder noted that "Evio has been our most valuable investor," citing not just capital but product insights, social media advocacy, and strategic introductions.[2]

Proprietary Founder Assessment Process

Drawing on Saki Georgiadis's background in talent management and CEO assessment, Evio has developed a data-driven methodology for evaluating founders as individuals, not just business concepts.[1] This process recognizes that founder quality, resilience, and mental health directly correlate with company outcomes—a thesis that remains underexplored in traditional venture capital.

Deep Sector Expertise

The team combines seasoned investors with successful mental health founders and operators, creating a rare hybrid of financial acumen and domain knowledge.[5] Matt Milford's GIMBHI platform provides real-time intelligence on the mental health innovation ecosystem, while Christy Maselli's operational scaling experience at Grow Therapy offers practical playbooks for portfolio companies navigating hypergrowth.

Hands-On Operating Support

Beyond capital and mentorship, Evio offers early-stage support in branding and marketing where relevant, positioning itself as a venture studio rather than a passive capital provider.[3] This operational engagement model reflects the team's founder backgrounds and their understanding of early-stage execution challenges.

Role in the Broader Tech Landscape

Evio operates at the intersection of three powerful macro trends: the normalization of mental health discourse, the professionalization of founder wellness, and the emergence of mental health as a critical infrastructure category.

The mental health technology market has experienced explosive growth as stigma has declined and digital therapeutics have proven clinical efficacy. Evio's early conviction in companies like Calm and BetterUp positioned the firm ahead of mainstream institutional capital, which has only recently begun allocating meaningfully to the sector. The firm's 2012 entry point into mental health investing predates the venture capital industry's broader awakening to the opportunity by nearly a decade.

Equally significant is Evio's role in legitimizing founder wellness as a venture capital concern. Historically, the startup ecosystem has romanticized founder burnout and treated mental health challenges as individual failings rather than systemic issues. By embedding founder wellbeing into its investment thesis, Evio challenges this narrative and signals to the broader ecosystem that sustainable company building requires sustainable founders. This positioning resonates particularly strongly with the post-2020 generation of founders who have witnessed the human costs of unchecked startup culture.

Evio also influences the ecosystem through thought leadership—GIMBHI's research reaches institutional investors, corporate strategists, and policymakers, shaping how the mental health innovation landscape is understood and funded.

Quick Take & Future Outlook

Evio represents a meaningful evolution in venture capital practice: the recognition that founder quality and founder wellbeing are inseparable from company outcomes. As the startup ecosystem matures and founder burnout becomes increasingly visible, this thesis will likely gain broader adoption. The firm's early positioning in mental health, combined with its operational expertise and founder-centric model, positions it well to capture significant value as the category scales.

Looking forward, Evio's influence will likely extend beyond its direct portfolio. As more venture firms adopt founder wellness programs and mental health support offerings, they will be following a playbook that Evio helped pioneer. The firm's continued success will depend on demonstrating that founder wellbeing correlates with superior financial returns—a thesis that, while intuitively compelling, requires rigorous validation through portfolio performance.

The broader question for Evio is whether its founder-centric model can scale without diluting the personalized support that currently differentiates it. As the firm grows its AUM and portfolio, maintaining the depth of founder engagement that has become its hallmark will be critical to sustaining competitive advantage in an increasingly crowded mental health venture capital space.